XellSmart Reports Positive Phase 1 Results for Parkinson's Cell Therapy XS411

XellSmart presented positive Phase 1 clinical data for its allogeneic cell therapy, XS411, for Parkinson's Disease. Results showed sustained improvements in motor function, quality of life, and molecular imaging biomarkers. The company also completed enrollment for its multicenter Phase 2 trial in China. XS411 uses iPSC-derived dopaminergic neural progenitor cells designed for use without patient-specific HLA matching, offering a potential off-the-shelf treatment.